At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 463 enrolled
Drug / intervention
Adalimumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Multicenter Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting
In Brief
A Phase 3 clinical trial evaluating Adalimumab for Ulcerative Colitis. Completed, enrolled 463 participants.
Detailed Summary
This study evaluated the quality of life (QOL) and economic impact of adalimumab treatment in participants with ulcerative colitis (UC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUlcerative Colitis
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 2012
Enrollment StartMay 2012
Primary CompletionApr 2015
TodayJul 2026
First PostedMar 12, 2012
Enrollment StartMay 1, 2012
Primary CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 14.3 years ago
Interventions
Adalimumabbiological
Adalimumab pre-filled syringe, administered by subcutaneous injection